Welcome to our dedicated page for Omnicell Com news (Ticker: OMCL), a resource for investors and traders seeking the latest updates and insights on Omnicell Com stock.
Omnicell, Inc. (NASDAQ: OMCL) is a healthcare technology company focused on intelligent medication management, and the OMCL news page on Stock Titan aggregates company-specific updates that matter to investors and healthcare observers. Omnicell describes itself as a leader in transforming the pharmacy and nursing care delivery model, with solutions that combine automation, AI-enabled intelligence, and expert services to support clinical, operational, and financial outcomes across all settings of care.
News related to Omnicell often centers on financial results, product innovation, and strategic developments. The company regularly issues earnings releases and guidance updates, discussing performance across categories such as connected devices, technical services, SaaS and Expert Services, and consumables. Press releases also cover events like conference presentations, investor Q&A sessions, and participation in industry meetings, providing context on how management communicates its strategy and outlook.
Product and technology announcements are another key theme in OMCL news. Examples include the launch of Omnicell Titan XT, an enterprise automated dispensing system powered by the OmniSphere cloud platform, and updates on OmniSphere certifications and capabilities. Omnicell also highlights initiatives such as specialty pharmacy services, URAC Health Care Management Certification, and innovation-focused events like Omnicell Illuminate and the IV TRUST Summit, which showcase developments in robotics, smart devices, software workflows, and data and analytics.
By following OMCL news, readers can monitor how Omnicell advances its vision of autonomous medication management, how it positions its solutions for health systems, retail and specialty pharmacies, and how management addresses risks and opportunities in a regulated healthcare environment. The Stock Titan news feed helps users track these announcements in one place for ongoing reference.
Omnicell, Inc. (NASDAQ:OMCL) will release its Q1 2022 financial results on April 28, 2022, after market close. The company will hold a conference call at 1:30 p.m. PT to discuss the results. Interested parties can join by calling (888) 550-5424 in the U.S. or (646) 960-0819 internationally, using Conference ID 5370673. The press release also highlights Omnicell's commitment to transforming pharmacy care through automation and technology to enhance operational efficiency and patient safety.
Omnicell, Inc. (NASDAQ: OMCL) has launched the IVX Station, an advanced IV compounding robot designed to improve efficiency and patient safety in pharmacy care. This technology enhances throughput speed threefold compared to existing solutions, addressing past reliability issues. Alongside this, the Winter 2022 Release introduces various improvements, including Omnicell One scorecards, a new refrigerated carousel for drug management, and upgraded XT Anesthesia Workstation features. These innovations aim to streamline pharmacy operations amidst regulatory complexities and rising healthcare costs.
Omnicell announced changes to its Board of Directors, revealing that Jim Judson and Bruce Smith will not seek reelection at the 2022 Annual Meeting, reducing the board size to nine members. Mary Garrett has been nominated to join the board, enhancing its expertise in digital transformation and healthcare technology. Garrett's impressive background includes a lengthy tenure at IBM and current board positions at other companies. Additionally, Dan Johnston will retire as Executive VP and Chief Legal Officer. These moves are part of Omnicell's strategy to strengthen leadership and improve healthcare solutions.
Omnicell, a leader in medication management, has entered a 10-year agreement with UMC Health System in Lubbock, Texas, to implement its cloud-based solutions for pharmacy automation and patient engagement. This partnership aims to enhance operational efficiency and patient safety through advanced pharmacy technology.
With UMC's significant demand increase and high uninsured rates in Texas, the solutions are expected to improve health outcomes in underserved communities.
Omnicell's Autonomous Pharmacy vision will drive performance and allow clinicians to focus more on patient care.
Omnicell, Inc. (NASDAQ:OMCL) reported a robust performance in 2021, achieving total revenues of $1.132 billion, a 27% increase from the previous year. Fourth quarter revenues reached $311 million, marking a 25% year-over-year growth. The company ended 2021 with a product backlog of $1.254 billion and completed acquisitions to expand its service offerings. For 2022, Omnicell expects revenues between $1.385 billion and $1.410 billion, with guidance aiming for non-GAAP earnings of $3.75 to $3.95 per share.
Omnicell, Inc. (NASDAQ:OMCL) will release its financial results for Q4 and full-year 2021 on February 14, 2022, after market close. A conference call and webcast to discuss these results will follow at 1:30 p.m. PT the same day. Interested parties can participate by calling (888) 550-5424 in the U.S. or (646) 960-0819 internationally. Omnicell focuses on improving pharmacy care delivery through automation and technology, with over 7,000 facilities utilizing its solutions globally.
Omnicell has acquired MarkeTouch Media for
Omnicell has acquired ReCept Holdings for $100 million, enhancing its Advanced Services portfolio in specialty pharmacy management. The acquisition is projected to boost Omnicell's non-GAAP EBITDA starting Q1 2023, aligning with its strategy to address the complex specialty pharmacy market. ReCept reported annual recurring revenue of $24 million as of September 30, 2021. This addition allows Omnicell to optimize specialty pharmacy programs and improve patient care, further solidifying its position in medication management solutions.
Omnicell announced its strategic acquisition of ReCept Holdings for
Omnicell, Inc. (NASDAQ: OMCL) announced its participation in two upcoming investor conferences. Randall Lipps, Chairman and CEO, along with Scott Seidelmann, Executive VP, will present at the Piper Sandler 33rd Annual Virtual Healthcare Conference on December 1, 2021, at 9:00 am ET. Additionally, Peter Kuipers, Executive VP and CFO, will appear at the 2021 Stephens Annual Investment Conference on December 3, 2021, at 10:00 am CT in Nashville, TN. Webcasts of both presentations will be accessible on the Omnicell website.